Abstract Details

Title Health concerns and treatment perspectives among US adults with current versus previous high-frequency headache/migraine and acute medication overuse: The Harris Poll Migraine Report Card Survey

Topic Headache

Presentation(s) P14 - Poster Session 14 (11:45 AM-12:45 PM)

Poster/Presentation
Number 2-007

Objective To report survey results comparing the experiences of individuals with current versus previous high-frequency headache/migraine (HFM) with acute medication overuse (AMO) and to characterize self-reported experience with care in these groups.

Background

Migraine is a disabling neurological disease that can negatively impact all aspects of life.

Design/Methods Respondents to this US, cross-sectional online survey qualified as living with migraine based on the validated “ID Migraine” screener. One group, labeled “current HFM+AMO,” were having ≥8 headache/migraine days/month and using ≥10 days/month of acute headache medication, while the second group (“previous HFM+AMO”) were now having ≤7 headache days/month with ≤9 days/month of acute headache medication use. Survey questions pertained to diagnosis, living with migraine, healthcare provider (HCP) communication, and treatment. Raw data were weighted to the US adult population.

Results

US adults (N=550) were categorized as having current (n=440; mean age, 41.1yr; mean headache days/month, 15.2; mean acute headache medication days/month, 17.4 or previous (n=110; 47.2yr; 4.2days; 4.1days) HFM+AMO. Racial demographics (White [current, 57%; previous, 75%], Hispanic [24%; 13%], Black [11%; 4%]) are similar to the US population. Despite most respondents with HFM+AMO describing their overall health as “good” or “excellent” (current, 64%; previous, 72%; P=ns), 80% of current HFM+AMO) vs 66% of previous HFM+AMO expressed concern with their health (P<0.05). Of the current and previous HFM+AMO groups, 37% and 35%, respectively, wish their HCP better understood their mental/emotional health. Respondents wish HCPs discussed headache management goals with them (current, 66%; previous, 43%; P<0.05) and roughly half of both groups worry about asking too many questions (current, 47%; previous, 54%; P=ns). Current preventive treatment use was low (15-16%; P=ns), while acute medication (28-37%) and over-the-counter medication (57-59%) use was higher.

Conclusions

This survey revealed several areas in which HCPs can improve care, including addressing mental health concerns and optimizing acute treatment.

Authors/Disclosures
Amaal J. Starling, MD, FAAN (Mayo Clinic) PRESENTER	Dr. Starling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Axsome Therapeutics. Dr. Starling has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Starling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medscape. Dr. Starling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Satsuma. Dr. Starling has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Miller Medical. Dr. Starling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. Dr. Starling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Salvia. Dr. Starling has received personal compensation in the range of $0-$499 for serving as a Consultant for Abbvie. Dr. Starling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal. Dr. Starling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for eNeura. Dr. Starling has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Woodberry Associates .
Roger Cady, MD (RK Consulting, LLC)	Dr. Cady has received personal compensation for serving as an employee of Lundbeck. Dr. Cady has stock in Alder Biopharmaceutical.
Dawn C. Buse, PhD (Dawn C. Buse, PhD)	Dr. Buse has received personal compensation for serving as an employee of Vector Psychometric Group. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie-Allergan. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Theranicsa. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie-Allergan. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Buse has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Current Pain and Headache Reports. The institution of Dr. Buse has received research support from Amgen. The institution of Dr. Buse has received research support from FDA. The institution of Dr. Buse has received research support from National Headache Foundation.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Steven Kymes	Steven Kymes has received personal compensation for serving as an employee of Lundbeck. Steven Kymes has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Journal of Ophthalmology. Steven Kymes has received research support from Emmes Corporation.

��ɫ��

��ɫ��